Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Summary

In this study, a method for synthesizing ultra-small populations of biocompatible nanoparticles was described, as well as several in vitro methods by which to assess their cellular interactions.

Abstract

Nanoparticle-based delivery vehicles have shown great promise for intracellular targeting applications, providing a mechanism to specifically alter cellular signaling and gene expression. In a previous investigation, the synthesis of ultra-small solid lipid nanoparticles (SLNs) for topical drug delivery and biomarker detection applications was demonstrated. SLNs are a well-studied example of a nanoparticle delivery system that has emerged as a promising drug delivery vehicle. In this study, SLNs were loaded with a fluorescent dye and used as a model to investigate particle-cell interactions. The phase inversion temperature (PIT) method was used for the synthesis of ultra-small populations of biocompatible nanoparticles. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylphenyltetrazolium bromide (MTT) assay was utilized in order to establish appropriate dosing levels prior to the nanoparticle-cell interaction studies. Furthermore, primary human dermal fibroblasts and mouse dendritic cells were exposed to dye-loaded SLN over time and the interactions with respect to toxicity and particle uptake were characterized using fluorescence microscopy and flow cytometry. This study demonstrated that ultra-small SLNs, as a nanoparticle delivery system, are suitable for intracellular targeting of different cell types.

Introduction

Nanoparticle-based delivery vehicles have shown great promise for intracellular targeting applications, providing a mechanism to specifically alter cellular signaling and gene expression. These vehicles can be loaded with drugs, proteins, and nucleic acids designed to impact cellular responses and achieve a desired effect in target tissues. Many types of nanocarriers have been explored for therapeutic and diagnostic benefit including lipids, polymers, silicon, and magnetic materials. These systems are attractive due to their potential for localized drug delivery, increased therapeutic concentration in target tissues, and reduction of systemic toxicity.

Solid lipid nanoparticles (SLNs) are a well-studied example of a nanoparticle delivery system that has emerged as a promising drug delivery vehicle in recent years. SLNs can be readily formulated for multiple applications including bio-sensing ¹, cosmetics ², and therapeutic delivery ^3-7. Their utility stems from the fact that they are comprised entirely of resorbable, nontoxic lipids, resulting in enhanced biocompatibility. During synthesis, lipophilic drugs can be incorporated into SLN vehicles, thereby increasing drug solubility and suitability for parenteral administration. SLN vehicles also help to stabilize encapsulated therapeutics, reducing their degradation and clearance, and maximizing therapeutic action. These vehicles are particularly well suited for long acting, controlled-release preparations due to their stability at body temperature ^3,4,8,9. Importantly, encapsulation of drugs in lipid nanoparticles alters the intrinsic pharmacokinetic profiles of the drug molecules. This provides a potential advantage by allowing the controlled release of drugs with a narrow therapeutic index. The release rate of SLN-incorporated therapeutics can be tuned based on the lipid degradation rate or the drug diffusion rate in the lipid matrix.

SLNs are often engineered to accumulate in specific target tissues. For example, their size (typically greater than 10 nm) potentiates retention in the circulation, where the leaky vasculature of tumor tissue facilitates deposition. In addition, the route of particle administration has been shown to alter biodistribution with the potential to target specific physiological structures such as lymph nodes ^10,11. Upon deposition in target tissues, achieving appropriate cellular interactions and eventual internalization of nanoparticles is challenging due to the ability of cell membranes to selectively control the flow of ions and molecules into and out of the cell ¹². To facilitate cellular uptake, it is possible to modify nanocarriers with specific ligands including peptides, small molecules, and monoclonal antibodies^13,14. Several mechanisms including both passive penetration and active transport of nanoparticles across the cell membrane have been previously described ^3,12,15. In general, it has been demonstrated that cell-nanoparticle interactions are influenced by the physicochemical properties of the nanoparticles including size, shape, surface charge and surface chemistry, in addition to cell-specific parameters such as cell type or cell cycle phase ¹².

A previous investigation demonstrated the synthesis of sub-10 nm SLNs for topical ¹⁶ and biomarker detection applications ¹ using the phase inversion temperature (PIT) method ¹⁷. This is a gentle synthesis method where ² the composition remains constant while the temperature is gradually changed. Continuous stirring of the heated solution, as it cools to RT results in a nanoemulsion. This process results in the synthesis of SLNs with smaller particle size¹ than that previously reported using various methods for the synthesis of lipid nanoparticles^17-22. The resulting size scale, less than 20 nm, provides an advantage for intracellular targeting applications due to increased surface area and the potential for enhanced cellular interactions.

A schematic of SLNs, designed to deliver a fluorescent dye or therapeutic, is shown in Figure 1. The SLNs consist of a lipid interior (e.g., linear alkane) allowing the incorporation of lipophilic compounds (e.g., dyes or therapeutics) and a surfactant exterior (e.g., linear nonionic surfactant) surrounded by water. In this study, SLNs were loaded with a fluorescent dye and used as a model to investigate particle-cell interactions. Primary human dermal fibroblasts and mouse dendritic cells were exposed to dye-loaded SLN over time in order to characterize interactions with respect to toxicity and particle uptake. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylphenyltetrazolium bromide (MTT) assay was utilized in order to establish appropriate dosing levels. Fluorescence microscopy and flow cytometry were two methods employed to examine particle uptake in vitro.

Figure 1. Schematic of SLN showing the major constituents. Please click here to view a larger version of this figure.

Protocol

1. Processing of SLNs

1. Synthesis of SLNs
   Note: Use the PIT method ^1,17,20 to prepare the sub-20 nm SLNs ¹.
   1. Use aseptic technique, bioreagents or cell culture grade reagents, and sterile materials (i.e., pipettes, spatulas, vials, etc.).
   2. Use a biosafety cabinet for the synthesis of SLNs (Figure 2).
   3. Combine 0.6 mg of fluorescent dye (Nile Red (NiR), NiR concentration is approximately 0.3 mg/ml) and 0.10 g of Heneicosane (Lipid, 5 wt/wt% lipid concentration) into a vial (15 ml), co-melt at 90 °C, and stir.
   4. Add 0.11 g polyoxyethylene (10) oleyl ether (Surfactant, 5.5 wt/wt% surfactant concentration). Co-melt the resulting mixture at 90 °C and stir.
   5. Add 1.79 g of sterile water to the mixture, heat to 90 °C, and stir until a transparent nanoemulsion is formed.
      Note: Under continued stirring and controlled cooling, SLNs are created. These conditions cause an inversion of the water-in-oil emulsion to an oil-in-water emulsion. Lipophilic molecules such as NiR partition to the lipid droplets.
   6. Prepare a nanoemulsion in parallel without adding the fluorescent dye, in order to serve as a control sample. Combine 0.10 g of Heneicosane and 0.11 g polyoxyethylene (10) oleyl ether into a vial (15 ml) co-melt at 90 °C, and stir.
      1. Add 1.79 g of sterile water to the mixture, heat to 90 °C, and stir until a transparent nanoemulsion is formed.
   7. Further sterilize each nanoemulsion using a sterile 0.2 µm filter.
   
   Figure 2. Schematic of synthesis of SLNs. Please click here to view a larger version of this figure.
2. Particle Size and Polydispersity
   1. Use dynamic light scattering (DLS) to measure the particle size and polydispersity of the SLNs ¹ using a glass cuvette and an instrument designed to measure particle size.
   2. Prior to the measurements of the samples, measure the particle sizes of two known standards following the manufacturer’s protocol for the standards preparation and measurement.
   3. Fill the glass cuvette with 1.5 ml of standard solution and measure the standard solution using the same measurement conditions as the samples.
      Note: Previous step was repeated for each standard.
   4. Measure the samples as prepared. For each, use the following experimental parameters: a run time of 100 sec, refractive index of water (1.33), viscosity of water at 20 °C (1.002 mPa·sec).
      Note: This technique uses frequency shifted light to measure the size of the nanoparticles.
   5. Report the average particle diameter and polydispersity of particle size distribution.
3. Melting Point and Latent Heat of Melting
   1. Use a differential scanning calorimeter (DSC) equipped with an auto-sampler and liquid nitrogen cooling source to investigate the thermal behavior of SLNs ¹.
   2. Pipette the as-prepared SLNs into a 40 µl aluminum pan with a mass of approximately 25 mg and hermetically seal the pan using a universal crimper press to minimize moisture loss during the DSC scan.
   3. Measure each nanoemulsion from 5 to 80 °C.
   4. Report the melting point and the latent heat of melting from the DSC plot, where the valley represents the melting point and the integral of the area under the curve in the DSC plot divided by the amount of material represents the latent heat of melting.

2. SLNs Interaction with Fibroblasts and Dendritic Cells

1. Culture of Primary Human Fibroblasts
   1. Culture primary human fibroblasts according to the manufacturer’s instructions in liquid medium for the culture of human dermal fibroblasts (medium 106), supplemented with the low serum growth supplement (LSGS) kit. Maintain cells in a humidified atmosphere at 37 °C, 5% CO₂ and subculture upon reaching 80% confluence.
   2. For both MTT and imaging analysis, seed cells in a 96-well plate, at a density of 2 x 10⁴ cells per well, and allow to equilibrate at 37 °C O/N prior to SLN exposure.
   3. At time zero, dilute SLNs in complete medium as indicated (Figure 4), with respect to lipid concentration, and add 10 μl per well to each replicate well in the 96-well plate.
   4. Maintain cells at 37 °C, 5% CO₂, during the incubation period.
2. MTT Toxicity Assay
   1. After 24 hr of incubation with SLNs, determine cellular viability using the MTT assay, according to the manufacturer’s protocol.
   2. Wash cells once and add fresh medium to each well (100 μl/well). Kill control wells by incubating in a 70% methanol solution for 10 min before replacing with fresh medium.
   3. Add MTT reagent (10 μl per well) to each well of the microplate and incubate O/N at 37 °C.
   4. After O/N incubation, solubilize intracellular formazin crystals with the provided detergent solution (100 μl per well) according to manufacturer’s protocol.
   5. After 3 hr of incubation at RT, obtain absorbance values at a measurement wavelength of 570 nm using a microplate reader.
      Note: MTT reagent used should be less than 1% (w/v) 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyl-tetrazolium bromide.
3. Fluorescence Microscopy
   1. At specific time points following dosing of fibroblasts with SLN, wash the fibroblasts twice with sterile phosphate buffered saline (PBS) and fix for 10 min with cold 70% methanol.
   2. After 10 min, replace the methanol with PBS and capture images using an inverted microscope, using a band pass (BP) 690/50 nm filter set.
4. Culture of Mouse Bone Marrow Dendritic Cells
   1. Induce mouse bone marrow-derived dendritic cells (BMDC) as previously described ^23,24. Briefly, plate single cell suspensions of C57BL/10 bone marrow in 100 mm Petri dishes at 2 x 10⁶/plate with recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF, 300 U/ml) and recombinant murine IL-4 (B cell stimulating factor, 200 U/ml). Change media every 3 days.
   2. On day 7, add NiR-loaded SLNs to the dishes at a final concentration of 0.5 and 5.0 µg/ml lipid and maintain the cells in a 37 °C, 5% CO₂ incubator for the desired length of exposure.
   3. Collect cells from the dishes by aspirating all the media in the plate, collecting it in a 50 ml tube, followed by thorough washing of the plate (to dislodge loosely adherent cells) with 5 ml of phosphate buffered saline (PBS) containing 4 mM ethylenediaminetetraacetic acid (EDTA). Collect the obtained cell suspension in the same 50 ml tube.
5. Assessment of SLNs Incorporation via Flow Cytometry
   1. Determine the concentration of the cell suspension obtained in point 2.4.3 and distribute 3x10⁵ cells into a 12 mm x 75 mm round bottom FACS tube.
   2. Wash the cells by adding 1 ml of PBS and then centrifuging the tubes for 5 min at 400 x g, at a temperature of 4 °C.
   3. Discard the supernatant and resuspend the pellet with 100 µl of PBS/2 mM EDTA/0.1% bovine serum albumin (BSA) (staining buffer) containing anti-CD11c-FITC monoclonal antibody (0.25 μg/ml final). Incubate for 30 min on ice in the dark.
   4. Wash the cells with 1 ml of PBS and then centrifuge the tubes for 5 min at 400 x g, at a temperature of 4 °C.
   5. Discard the supernatant and resuspend each pellet with 400 µl of staining buffer. The cells are now ready for acquisition of the samples with a flow cytometer (possibly equipped with blue and red lasers).
   6. Using flow cytometry analysis software, assess the level of incorporation of SLNs by DC by gating on the population of CD11c+ cells (FITC positive) and comparing the intensity of SLNs-associated fluorescence (measured in the PerCP-Cy5.5 or APC channels).

Results

The PIT method was used to synthesize the SLNs and the phase inversion temperature was determined utilizing a water bath. The samples were slowly heated and gently agitated until the solution appeared clear. The phase inversion temperature for the SLNs made using heneicosane lipid is 45 °C. Table 1 summarizes the particle size, polydispersity, melting point and latent heat of melting for the SLNs. The SLNs synthesized using the processing conditions described above resulted in control SLNs and NiR-loaded...

Discussion

In this study, the synthesis of SLNs and their applicability for intracellular targeting applications were explored. These biocompatible nanoparticles have shown promise as delivery vehicles for multiple applications including drug delivery, gene silencing, and vaccine technologies ^25-30. Ultra-small SLNs were synthesized using a facile process, and their interactions with primary skin cells and primary immune cells were explored. SLNs were designed to include encapsulation of a fluorescent dye (NiR), which se...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Nile Red (NiR)	Sigma	19123	BioReagent, suitable for fluorescence, ≥98.0%
Heneicosane	Aldrich	286052	98%
Brij O10	Sigma	P6136	Brij 97, C18-1E10, Polyoxyethylene (10) oleyl ether
Water	Sigma	W3500	Sterile-filtered, BioReagent, suitable for cell culture
Syringe Filter 0.2 µm Supor Membrane Low Protein Binding	Life Sciences	PN4612	Non-Pyrogenic
Nanotrac Ultra	Microtrac	serial number U1985IS	Instrument
Differential Scanning Calorimeter	Mettlet-Toledo		Instument
Primary human fibroblasts	Life Technologies	C-004-5C	Neonatal (HDFn)
Medium 106	Life Technologies	M-106-500	A sterile, liquid medium for the culture of human dermal fibroblasts.
Low Serum Growth Supplement Kit (LSGS Kit)	Life Technologies	S-003-K	All the components of complete LSGS
MTT Cell Proliferation Assay Kit	Trevigen	4890-025-K	Sensitive kit for the measurement of cell proliferation based upon the reduction of the tetrazolium salt, 3-[4,5-dimethylthiazol-2- yl]-2,5-diphenyl-tetrazolium bromide (MTT)
Safire2 microplate reader	Tecan	----	Instrument
Phosphate buffered saline	Sigma	P5493	For molecular biology
Recombinant murine GM-CSF	Peprotech	315-03	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Recombinant murine IL-4	Peprotech	214-14	>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.